Announcements
- Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
- Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
- Tempest Reports Year End 2023 Financial Results and Provides Business Update
- Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
- Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
- Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
- Tempest Adopts Limited Duration Stockholder Rights Plan
More ▼
Key statistics
As of last trade, Tempest Therapeutics Inc (3OS:FRA) traded at 3.21, 1,755.49% above the 52 week low of 0.173 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.21 |
---|---|
High | 3.21 |
Low | 3.21 |
Bid | 3.26 |
Offer | 3.32 |
Previous close | 3.17 |
Average volume | 790.89 |
---|---|
Shares outstanding | 22.19m |
Free float | 22.18m |
P/E (TTM) | -- |
Market cap | 77.23m USD |
EPS (TTM) | -1.96 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:04 BST.
More ▼